ABM Therapeutics is at the forefront of innovative drug discovery, particularly focusing on small molecule targeted therapies for brain cancers, including glioblastoma multiforme (GBM) and brain metastases from various cancers such as lung, breast, and melanoma. Their lead compound, ABM-1310, is a highly potent and selective BRAF inhibitor designed to effectively penetrate the brain and target BRAF V600E mutations, which are present in approximately 8% of all cancers. This compound has received Investigational New Drug (IND) approval in both the USA and China, allowing it to progress into first-in-human clinical trials. 

In addition to ABM-1310, ABM Therapeutics is developing ABM-168, an allosteric MEK inhibitor that also demonstrates good brain penetration and is intended to be used in combination with other oncogenic driver inhibitors to enhance therapeutic efficacy. Another promising candidate, ABM-2752, is a potent allosteric HPK1 inhibitor that aims to activate the immune response against cancer by inhibiting a kinase that negatively regulates T-cell activity. The company is also exploring additional compounds targeting Src/STAT3 and Wnt/b-catenin signaling pathways, which are crucial in addressing cancer metastasis and drug resistance, with the potential for synergistic effects when combined with MAPK inhibitors.

China

ABM is an innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer. It was founded in 2015 by a group of biotech and pharmaceutical industry veterans with more than 20 years of experience in the development of neurological drugs and enterprise management from North America. Since establishment, ABM is building its broad proprietary pipeline internally to construct a brain medicine R&D platform through collaborations with CROs and partners. 

ABM Therapeutics

Company Details